Insights from 2025 ASCO® GI Annual Meeting
Video Player is loading.
10 seconds
Playback speed
ESMO GI 2024 & ASCO® GI 2025 Insights: Cabozantinib vs. Placebo for R/R Advanced NET - Updated Results From the Ph3 CABINET Trial
On March 26, 2025, the Food and Drug Administration approved cabozantinib (Cabometyx) for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET) and well-differentiated extra-pancreatic neuroendocrine tumors (epNET).
Comments 0
Login to view comments.
Click here to Login
